Analysts’ Top Healthcare Picks: Organon (OGN), Agenus (AGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Organon (OGN – Research Report), Agenus (AGEN – Research Report) and Merck & Company (MRK – Research Report) with bullish sentiments.

Organon (OGN)

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on Organon, with a price target of $33.00. The company’s shares closed last Wednesday at $23.45.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 21.5% and a 44.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Entrada Therapeutics Inc, and Bristol-Myers Squibb.

Organon has an analyst consensus of Moderate Buy, with a price target consensus of $30.60.

See Insiders’ Hot Stocks on TipRanks >>

Agenus (AGEN)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus, with a price target of $8.00. The company’s shares closed last Wednesday at $1.29, close to its 52-week low of $1.18.

According to TipRanks.com, Mamtani ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -20.6% and a 25.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Checkpoint Therapeutics.

Agenus has an analyst consensus of Strong Buy, with a price target consensus of $7.66, implying a 484.7% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

Merck & Company (MRK)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $130.00. The company’s shares closed last Wednesday at $106.62.

According to TipRanks.com, Goldstein has 0 stars on 0-5 stars ranking scale with an average return of -4.0% and a 34.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $126.00, which is a 18.6% upside from current levels. In a report issued on July 25, Truist Financial also maintained a Buy rating on the stock with a price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OGN:

• Early notable gainers among liquid option names on August 8th
• Organon narrows FY23 revenue view to $6.25B-$6.45B, consensus $6.28B
• Organon reports Q2 EPS $1.31 , consensus 97c
• Samsung Bioepis, Organon announces results from study of SB5
• Dare Bioscience to receive $1.0M in July from Organon under license agreement